TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06853223: This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Sponsor: University of California, San Francisco · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT06853223 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06853223 Rescue Dossier →